317 related articles for article (PubMed ID: 29569806)
1. Effect of everolimus on skin lesions in patients treated for subependymal giant cell astrocytoma and renal angiomyolipoma: final 4-year results from the randomized EXIST-1 and EXIST-2 studies.
Franz DN; Budde K; Kingswood JC; Belousova E; Sparagana S; de Vries PJ; Berkowitz N; Ridolfi A; Bissler JJ
J Eur Acad Dermatol Venereol; 2018 Oct; 32(10):1796-1803. PubMed ID: 29569806
[TBL] [Abstract][Full Text] [Related]
2. The effect of everolimus on renal angiomyolipoma in pediatric patients with tuberous sclerosis being treated for subependymal giant cell astrocytoma.
Bissler JJ; Franz DN; Frost MD; Belousova E; Bebin EM; Sparagana S; Berkowitz N; Ridolfi A; Kingswood JC
Pediatr Nephrol; 2018 Jan; 33(1):101-109. PubMed ID: 28993887
[TBL] [Abstract][Full Text] [Related]
3. The effect of everolimus on renal angiomyolipoma in patients with tuberous sclerosis complex being treated for subependymal giant cell astrocytoma: subgroup results from the randomized, placebo-controlled, Phase 3 trial EXIST-1.
Kingswood JC; Jozwiak S; Belousova ED; Frost MD; Kuperman RA; Bebin EM; Korf BR; Flamini JR; Kohrman MH; Sparagana SP; Wu JY; Brechenmacher T; Stein K; Berkowitz N; Bissler JJ; Franz DN
Nephrol Dial Transplant; 2014 Jun; 29(6):1203-10. PubMed ID: 24729041
[TBL] [Abstract][Full Text] [Related]
4. Effect of everolimus on renal function in patients with tuberous sclerosis complex: evidence from EXIST-1 and EXIST-2.
Bissler JJ; Budde K; Sauter M; Franz DN; Zonnenberg BA; Frost MD; Belousova E; Berkowitz N; Ridolfi A; Christopher Kingswood J
Nephrol Dial Transplant; 2019 Jun; 34(6):1000-1008. PubMed ID: 30053159
[TBL] [Abstract][Full Text] [Related]
5. Everolimus long-term use in patients with tuberous sclerosis complex: Four-year update of the EXIST-2 study.
Bissler JJ; Kingswood JC; Radzikowska E; Zonnenberg BA; Belousova E; Frost MD; Sauter M; Brakemeier S; de Vries PJ; Berkowitz N; Voi M; Peyrard S; Budde K
PLoS One; 2017; 12(8):e0180939. PubMed ID: 28792952
[TBL] [Abstract][Full Text] [Related]
6. Everolimus for renal angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: extension of a randomized controlled trial.
Bissler JJ; Kingswood JC; Radzikowska E; Zonnenberg BA; Frost M; Belousova E; Sauter M; Nonomura N; Brakemeier S; de Vries PJ; Berkowitz N; Miao S; Segal S; Peyrard S; Budde K
Nephrol Dial Transplant; 2016 Jan; 31(1):111-9. PubMed ID: 26156073
[TBL] [Abstract][Full Text] [Related]
7. Long-Term Use of Everolimus in Patients with Tuberous Sclerosis Complex: Final Results from the EXIST-1 Study.
Franz DN; Belousova E; Sparagana S; Bebin EM; Frost MD; Kuperman R; Witt O; Kohrman MH; Flamini JR; Wu JY; Curatolo P; de Vries PJ; Berkowitz N; Niolat J; Jóźwiak S
PLoS One; 2016; 11(6):e0158476. PubMed ID: 27351628
[TBL] [Abstract][Full Text] [Related]
8. Rapamycin and rapalogs for tuberous sclerosis complex.
Sasongko TH; Ismail NF; Zabidi-Hussin Z
Cochrane Database Syst Rev; 2016 Jul; 7(7):CD011272. PubMed ID: 27409709
[TBL] [Abstract][Full Text] [Related]
9. EFFECTS: an expanded access program of everolimus for patients with subependymal giant cell astrocytoma associated with tuberous sclerosis complex.
Fogarasi A; De Waele L; Bartalini G; Jozwiak S; Laforgia N; Verhelst H; Petrak B; Pedespan JM; Witt O; Castellana R; Crippa S; Gislimberti G; Gyorsok Z
BMC Neurol; 2016 Aug; 16():126. PubMed ID: 27502586
[TBL] [Abstract][Full Text] [Related]
10. Everolimus compliance and persistence among tuberous sclerosis complex patients with renal angiomyolipoma or subependymal giant cell astrocytoma.
Song X; Said Q; Tran O; Krueger DA; Bissler J
Curr Med Res Opin; 2019 Jun; 35(6):1103-1110. PubMed ID: 30550347
[TBL] [Abstract][Full Text] [Related]
11. Assessing the outcomes of everolimus on renal angiomyolipoma associated with tuberous sclerosis complex in China: a two years trial.
Cai Y; Guo H; Wang W; Li H; Sun H; Shi B; Zhang Y
Orphanet J Rare Dis; 2018 Mar; 13(1):43. PubMed ID: 29587809
[TBL] [Abstract][Full Text] [Related]
12. Angiomyolipoma rebound tumor growth after discontinuation of everolimus in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis.
Bissler JJ; Nonomura N; Budde K; Zonnenberg BA; Fischereder M; Voi M; Louveau AL; Herbst F; Bebin EM; Curatolo P; Zonta A; Belousova E
PLoS One; 2018; 13(9):e0201005. PubMed ID: 30192751
[TBL] [Abstract][Full Text] [Related]
13. The Efficacy of Everolimus for Facial Angiofibromas in Tuberous Sclerosis Complex Patients Treated for Renal Angiomyolipoma/Subependymal Giant Cell Astrocytoma.
Wei CC; Hsiao YP; Gau SY; Wu YT; Wu CT; Wu MH; Tsai JD
Dermatology; 2021; 237(3):444-449. PubMed ID: 33032292
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial.
Franz DN; Belousova E; Sparagana S; Bebin EM; Frost M; Kuperman R; Witt O; Kohrman MH; Flamini JR; Wu JY; Curatolo P; de Vries PJ; Whittemore VH; Thiele EA; Ford JP; Shah G; Cauwel H; Lebwohl D; Sahmoud T; Jozwiak S
Lancet; 2013 Jan; 381(9861):125-32. PubMed ID: 23158522
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness and safety of everolimus treatment in patients with tuberous sclerosis complex in real-world clinical practice.
Cockerell I; Christensen J; Hoei-Hansen CE; Holst L; Grenaa Frederiksen M; Issa-Epe AI; Nedregaard B; Solhoff R; Heimdal K; Johannessen Landmark C; Lund C; Nærland T
Orphanet J Rare Dis; 2023 Dec; 18(1):377. PubMed ID: 38042867
[TBL] [Abstract][Full Text] [Related]
16. Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised EXIST-1 study.
Franz DN; Belousova E; Sparagana S; Bebin EM; Frost M; Kuperman R; Witt O; Kohrman MH; Flamini JR; Wu JY; Curatolo P; de Vries PJ; Berkowitz N; Anak O; Niolat J; Jozwiak S
Lancet Oncol; 2014 Dec; 15(13):1513-1520. PubMed ID: 25456370
[TBL] [Abstract][Full Text] [Related]
17. Efficacy, Retention and Tolerability of Everolimus in Patients with Tuberous Sclerosis Complex: A Survey-Based Study on Patients' Perspectives.
Willems LM; Rosenow F; Schubert-Bast S; Kurlemann G; Zöllner JP; Bast T; Bertsche A; Bettendorf U; Ebrahimi-Fakhari D; Grau J; Hahn A; Hartmann H; Hertzberg C; Hornemann F; Immisch I; Jacobs J; Klein KM; Klotz KA; Kluger G; Knake S; Knuf M; Marquard K; Mayer T; Meyer S; Muhle H; Müller-Schlüter K; von Podewils F; Ruf S; Sauter M; Schäfer H; Schlump JU; Syrbe S; Thiels C; Trollmann R; Wiemer-Kruel A; Wilken B; Zukunft B; Strzelczyk A
CNS Drugs; 2021 Oct; 35(10):1107-1122. PubMed ID: 34275102
[TBL] [Abstract][Full Text] [Related]
18. Everolimus for subependymal giant cell astrocytoma: 5-year final analysis.
Franz DN; Agricola K; Mays M; Tudor C; Care MM; Holland-Bouley K; Berkowitz N; Miao S; Peyrard S; Krueger DA
Ann Neurol; 2015 Dec; 78(6):929-38. PubMed ID: 26381530
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic effect of everolimus on small renal angiomyolipoma in cases of tuberous sclerosis complex-related epilepsy and subependymal giant cell astrocytoma.
Hatano T; Yuri Y
Asian J Surg; 2023 Mar; 46(3):1236-1237. PubMed ID: 36031512
[No Abstract] [Full Text] [Related]
20. Safety of Everolimus in Patients Younger than 3 Years of Age: Results from EXIST-1, a Randomized, Controlled Clinical Trial.
Jóźwiak S; Kotulska K; Berkowitz N; Brechenmacher T; Franz DN
J Pediatr; 2016 May; 172():151-155.e1. PubMed ID: 26858193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
